Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Cancer 8, 484–485 (1 July 2008) | doi:10.1038/nrc2424
Signalling: Survival of the sweetest
Abstract
Response rates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in cancer treatment have been surprisingly and disappointingly low. Zhang Weihua and colleagues now shed some light on this issue by revealing a kinase-independent function of EGFR in maintaining cell survival.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
